Resverlogix Closes US$2 Million Shares-for-Interest Private Placement
Calgary, Alberta--(Newsfile Corp. - May 19, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") announced today that it has closed a $2,760,057 (US$2,000,000) shares-for-interest private placement (the "Transaction") with an arm's length subscriber (the "Subscriber"). Under the terms of the Transaction, the Subscriber subscribed for 26,864,133 common shares at CAD$0.103 per share, equal to the applicable 5-day volume-weighted average price, for aggregate proceeds of CAD$2,760,057 (US
Technologies, Biotechnologies, Soins de santé et hôpitaux
2026-05-19 5:15 PM EDT | Resverlogix Corp.
Maxwell Biosciences' Claromers Destroy Epstein-Barr
Austin, Texas--(Newsfile Corp. - May 19, 2026) - Maxwell Biosciences, a global health technology company pioneering a new category of immune-inspired, broad spectrum small molecules called Claromers®, today announces Claromers destroy Epstein-Barr virus, according to a third-party lab study.
Biotechnologies, Pharmaceutique
2026-05-19 9:00 AM EDT | Maxwell Biosciences, Inc.
NorthPalm Capital Launches as AI-Augmented Investment Company
Toronto, Ontario--(Newsfile Corp. - May 19, 2026) - NorthPalm Capital Corp. (CSE: NP) ("NorthPalm" or the "Company") is pleased to announce the launch of NorthPalm Capital[1], an AI-augmented investment company focused on identifying and supporting high-growth opportunities across technology and digital asset sectors. The launch reflects NorthPalm's evolution into a leaner, high-conviction investment company with a modern approach to sourcing, evaluating, and act
Biotechnologies, Soins de santé et hôpitaux, Santé
2026-05-19 8:36 AM EDT | NorthPalm Capital Corp.
Neural Portfolio Company Hanf.com Expands German Retail Footprint with New Muhldorf am Inn Store and Four Refurbished Locations
Toronto, Ontario--(Newsfile Corp. - May 19, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, together with its portfolio company CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of Germany's leading CBD retailers, is pleased to announce the opening of a new Hanf.
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-05-19 7:30 AM EDT | Neural Therapeutics Inc.
InMed Pharmaceuticals Amends Preferred Investment Options
Vancouver, British Columbia--(Newsfile Corp. - May 19, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces that it has entered into an amending agreement with Armistice Capital Master Fund Ltd. ("Armistice") in respect of certain outstanding preferred investment options held b
Biotechnologies, Pharmaceutique
2026-05-19 6:00 AM EDT | InMed Pharmaceuticals
Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities
Montreal, Quebec--(Newsfile Corp. - May 19, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the expansion of internal capabilities to execute critical stages of its ACCUM®-enabled Antibody Drug Conjugates ("ADC") development pipeline. The Company has strengthened its purification, analytical characterization, conjugation
Biotechnologies, Pharmaceutique, Santé
2026-05-19 3:15 AM EDT | Defence Therapeutics Inc.
Microbiome Labs launches EpicDefense on Amazon
Franklinton, North Carolina--(Newsfile Corp. - May 18, 2026) - Microbiome Labs™, a leader in microbiome-based solutions, announces the official launch of EpicDefense™ on Amazon, expanding consumer access to its latest microbiome-focused immune-support formula. EpicDefense is formulated to support the body's natural defenses and promote respiratory com
2026-05-18 10:00 AM EDT | Microbiome Labs
Tate & Lyle Expands Collaboration with BioHarvest Sciences to Accelerate Next-Generation Sweetener Innovation
British Columbia and Rehovot, Israel--(Newsfile Corp. - May 18, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis™ technology and sustainable plant-based molecule development, today announced the expansion of its collaboration with Tate & Lyle PLC (Tate & Lyle), a global leader in ingredient solutions for healthier food and beverages, broadening the scope of their
Biotechnologies, Pharmaceutique, Santé
2026-05-18 7:00 AM EDT | BioHarvest Sciences Inc.
OS Therapies Reports First Quarter 2026 Financials and Provides Business Update
$5.5 million financing that closed on April 2, 2026 together with $5.7 million in capital raised in Q1-2026, expected to provide Company with cash runway into 2027 $4.5 million of accrued VAT refunds and R&D refundable tax credits from UK subsidiary begin maturing, including $1.9 million VAT cash refund expected in June 2026 Successful EMA and Australia TGA (ATGA) meetings aligned around use of existing biomarker and pending release of 3-year overall
2026-05-18 6:30 AM EDT | OS Therapies
OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026
New York and Rockville, Maryland--(Newsfile Corp. - May 15, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, listeria-based cancer immunotherapies, announced that it will announce first quarter 2026 financials and provide a business update on the morning of Monday May 18, 2026. About OS Therapies OS Therapies is a clinical stage oncology company focused on the identification, development,
2026-05-15 4:05 PM EDT | OS Therapies
Restart Life Sciences Advances New Product Relaunch Utilizing Acquired Intellectual Property Portfolio
Vancouver, British Columbia--(Newsfile Corp. - May 15, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to provide an operational update regarding the strategic trademark licensing agreement previously announced on March 14, 2025. Over the past year, management has been actively working toward product launches leveraging the intellectual property (IP) and valuable business insights acquired under the agreement. Th
Technologies, Biotechnologies, Santé
2026-05-15 4:00 PM EDT | Restart Life Sciences Corp.
MustGrow Announces Market Awareness Services and Investor Relations Agreements
Saskatoon, Saskatchewan--(Newsfile Corp. - May 14, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") announces the following market awareness services and investor relations agreements to increase visibility and awareness to MustGrow. Disclosure is made in accordance with the requirements of the TSX Venture Exchange (the "TSXV"). Market One Media Group MustGrow has entered into a media services agreeme
Agriculture, Biotechnologies, Cannabis, Sélectionneurs de cannabis
2026-05-14 5:14 PM EDT | MustGrow Biologics Corp.
OS Therapies Appoints Industry Leader Dr. Craig Eagle as Chief Medical Advisor
Appointment strengthens medical, regulatory, and commercial leadership as Company prepares to complete early market access regulatory filings in the U.S., U.K, Europe and Australia in anticipation of OST-HER2 approval decisions expected by year-end 2026 Upcoming FDA Pre-BLA meeting will focus on the use of recent seroconversion biomarker data as a key surrogate clinical efficacy endpoint to support a BLA for OST-HER2 under the Accelerated Approval Pr
2026-05-14 7:30 AM EDT | OS Therapies
BioHarvest Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
Quarterly revenue up 8% year over year; Annual revenue guidance range remains at $42-$48 million CDMO fragrance and Saffron projects reach successful milestones; First quarter CDMO revenue grew 135% YoY VINIA brand customer base grows to 90,000 active users as of the end of April Two-lens
Biotechnologies, Pharmaceutique, Santé
2026-05-14 7:00 AM EDT | BioHarvest Sciences Inc.
TempraMed Announces Granted Indian Design Patent for VIVI Cap Smart Product
Highlights Granted Patent covers the design of VIVI Cap Smart™ across major international, growing market Strengthens the Company's intellectual property position in one of the world's largest healthcare and consumer markets Supports commercialization strategy and strategic discussions with appliance manufacturers Design term extends through May 16, 2039 Company enters into f
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-05-14 3:00 AM EDT | TempraMed Technologies Ltd.
BioHarvest Sciences Appoints New Head of Business Development for its CDMO Division
British Columbia and Rehovot, Israel--(Newsfile Corp. - May 13, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced the appointment of Nedira Salzman-Frenkel to Vice President of Business Development. Ms. Salzman-Frenkel's role will be instrumental for sourcing and managing new prospective contracts across the pharmaceutical, nutraceu
Biotechnologies, Pharmaceutique, Santé
2026-05-13 5:32 PM EDT | BioHarvest Sciences Inc.
PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company, today announced that Sairiyo Therapeutics Inc. ("Sairiyo"), a company 49% owned by PharmaTher and 51% owned by PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF), is pursuing its strategic plans to focus on the clinical development of its patented enteric-coated oral Cepharanthine ("PD-001") as a potential therapeutic candidate
Biotechnologies, Pharmaceutique
2026-05-13 10:11 AM EDT | PharmaTher Holdings Ltd.
PharmaDrug Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of natural medicines is is pleased to announce that Sairiyo Therapeutics Inc. ("Sairiyo"), a company 51% owned by PharmaDrug and 49% owned by PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher"), is pursuing its strategic plans to focus on the clinical devel
Biotechnologies, Cannabis, Psychédéliques, Producteurs de cannabis
2026-05-13 8:50 AM EDT | PharmaDrug Inc.
BioHarvest Sciences Announces Successful Completion of Stage 1 Development of Saffron Composition for Nutraceutical and Culinary Applications
- CDMO program advances to Stage 2 of development agreement valued at $1.125 million -Advancement of sustainable solution for the production of saffron, one of the world's most valuable and health-promoting botanicals - In addition to future commercial manufacturing royalties, BioHarvest also holds a 25% ownership position in Saffron Composition Vancouver, British Colum
Biotechnologies, Pharmaceutique, Santé
2026-05-13 8:00 AM EDT | BioHarvest Sciences Inc.
Restart Life Sciences Leverages Amazon Logistics for Strategic Entry of Holy Crap Foods into U.S. Market
Vancouver, British Columbia--(Newsfile Corp. - May 13, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that its wholly owned subsidiary, Holy Crap Foods Inc., is preparing for its official entry into the United States market. This expansion marks a pivotal milestone in the Company's North American growth strategy under its new leadership team. While the brand previously maintained a broader internatio
Technologies, Biotechnologies, Santé
2026-05-13 6:00 AM EDT | Restart Life Sciences Corp.